AV Synchronous Leadless Pacing: The Next Step in the Journey

Published: 28 October 2020
Likes: 2
Average (rating)
No ratings
Your rating

Overview

In this webinar, experts will talk about the latest evidence on leadless pacing and the newest addition to the leadless pacing portfolio: Micra AV. This will include research and feasibility studies, latest data and patient selection considerations.

Key References

1. Duray G et al. Long-term performance of a transcatheter pacing system: 12-Month results from the Micra Transcatheter Pacing Study. Heart Rhythm 2017; 14: 702-709

2. Roberts P et al. A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. Heart Rhythm 2017; 14: 1375-1379

3. Reynolds D et al. A leadless Intracardiac Transcatheter Pacing System. N Engl J Med 2016; 374(6): 533-541

4. Ritter P et al. The rationale and design of the Micra Transcatheter Pacing Study: safety and efficacy of a novel miniaturized pacemaker. Europace 2015; 17(5): 807-813

5. Piccini JP et al. Patient selection, pacing indications, and subsequent outcomes with de novo leadless single-chamber VVI pacing. Europace 2019; 21: 1686-1693

6. Chinitz LA. Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: Results from the Micra atrioventricular feasibility studies. Heart Rhythm 2018; 15: 1363–1371

7. Steinwender C. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: Results from the MARVEL 2 study. JACC Clin Electrophysiol. 2020; 6(1): 94-106

8. Garweg C. Predictors of Atrial Mechanical Sensing and Atrioventricular Synchrony with a Leadless Ventricular Pacemaker: Results from the MARVEL 2 Study. Heart Rhythm. Journal pre-proof.

Load more

Learning objective

  • The results of the latest Micra clinical studies with Micra VR, reflecting the real-world results, 5 years after it was first launched in Europe
  • The studies that resulted in the development of Micra AV (the second-generation leadless pacemaker, designed to provide AV Synchrony), which has been recently introduced in Europe, the early experience and patient selection considerations

Audience

  • Cardiologists and electrophysiologists not involved in the implantation of leadless pacemakers, but who have patients who could benefit from the therapy.
  • Cardiologists implanting or planning to implant leadless pacemakers.

Agenda

17:00

Introduction-C. Steinwender

17:05

Leadless ventricular pacing: Indications, clinical results and learnings -C. Pepper

17:20

Q&A – poll -All

17:30

Development of and early experience with AV synchronous leadless pacing -L. Boersma

17:45

Q&A – poll -All

17:55

Conclusions-C. Steinwender

Medtronic Inc.